VBWG
Data alert

Statins and safety: Overview for patient care

Hypercholesterolemia is one of the major modifiable risk factors for coronary heart disease. To reach target cholesterol levels, many patients require a combination of lifestyle changes and lipid-lowering therapy.1 Over the last decade clinical trials have demonstrated that low-density lipoprotein cholesterol (LDL-C) reduction with statin therapy decreases the risk of cardiac events substantially in patients with coronary heart disease, including those with normal cholesterol levels,2,3 and in healthy high-risk patients irrespective of serum cholesterol level.4,5

References are listed at the end of the Data Alert.





04DA_SAFETY.ppt

Download 04DA_SAFETY.ppt (6 slides - 1.3MB)

Slide 1 Slide 2 Slide 3 Slide 4 Slide 5 Slide 6
Data_Alert.pdf (1.5MB)Data_Alert.pdf (1.5MB)


coronaryhypercholesterolemiamodifiablesafetystatins

Related at vwbg.org

ASCOT-LLA: Extending benefits of statins to hypertensive patients

Hypertension and hypercholesterolemia frequently coexist and the interaction of these important risk factors increases cardiovascular risk considerably.

ASTEROID trial

Results from ASTEROID: A Study to evaluate the Effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden

Vascular Biology in Clinical Practice © Vol. 6, No. 2

High-dose statins and early benefit in ACS: Role of inflammation

This monograph, High-dose statins and early benefit in ACS: Role of inflammation , is offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.
More related